Dr. Daniel Landry, Baystate Medical Center, notes the dramatic and sustained reduction in CLABSI rates using ClearGuard HD caps in the two prospective multicenter randomized controlled trials encompassing more than 533,000 catheter-days in his accompanying editorial. He recommends use of antimicrobial catheter caps for the purpose of preventing CLABSI as a component of a global strategy to reduce bloodstream infections.
ClearGuard HD caps are also included as a specific prevention strategy for central venous catheters to reduce the risk of bloodstream infection by Eduardo Lacson, Jr., MD at Tufts University School of Medicine, and Alan Kliger, MD, of Yale School of Medicine. They provide an overview of the two trials using ClearGuard HD caps and conclude central venous catheter caps with chlorhexidine-coated rods decrease the risk of blood stream infections compared with standard caps or isopropanol-containing caps.
The July edition of NephSAP is part of the Nephrologists Transforming Dialysis Safety (NTDS) project, an initiative funded by the Centers for Disease Control and Prevention (CDC) aimed at engaging nephrologists to promote infection prevention in dialysis facilities.
It's gratifying to see the CDC and ASN recognize ClearGuard HD caps in this special edition of NephSAP, said Doug Killion, President and CEO of Pursuit Vascular. We share a common vision with NTDS in targeting zero infections, and ClearGuard HD caps help make this goal a reality.